Literature DB >> 24211123

Re-irradiation with interstitial pulsed-dose-rate brachytherapy for unresectable recurrent head and neck carcinoma.

Vratislav Strnad1, Michael Lotter2, Stephan Kreppner2, Rainer Fietkau2.   

Abstract

PURPOSE: To assess the long-term results of protocol-based interstitial pulsed-dose-rate (PDR) brachytherapy combined with simultaneous chemotherapy in selected patients with recurrent head and neck tumors not amenable to salvage surgery. METHODS AND MATERIALS: A total of 51 patients with recurrent head and neck cancer were treated with interstitial PDR brachytherapy. Forty patients (78%) had salvage brachytherapy alone using a median total dose of 60 Gy. Salvage brachytherapy in combination with external beam therapy was performed in 11 patients (22%) using a median total dose of DREF=27 Gy. Simultaneously with the PDR brachytherapy, a concomitant chemotherapy was administered in 35/51 (69%) of patients. The analysis was performed after a median followup of 58 months.
RESULTS: Local control rates calculated according to Kaplan-Meier after 2 and 5 years were 71% and 57%, respectively. Comparing results of salvage PDR brachytherapy with or without simultaneous chemotherapy, the 5-year local recurrence-free survival rates were 78.9% vs. 38.5% (p=0.01), respectively. No other patient or treatment-related parameters had a significant influence on treatment results. A total of 9/51 (17.7%) and 6/51 (11.8%) patients developed soft-tissue necrosis or bone necrosis, respectively, but only 2% of patients required surgical treatment.
CONCLUSIONS: PDR interstitial brachytherapy with pulse doses between 0.4 and 0.7 Gy/h/24 h with simultaneous chemotherapy is an effective and safe option for curative therapy in selected patients with head and neck cancer in previously irradiated areas, which are not suitable for salvage surgery.
Copyright © 2014 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; Interstitial brachytherapy; Local recurrence; PDR brachytherapy; Re-irradiation; Salvage brachytherapy

Mesh:

Year:  2013        PMID: 24211123     DOI: 10.1016/j.brachy.2013.10.008

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  10 in total

Review 1.  A review of the clinical experience in pulsed dose rate brachytherapy.

Authors:  Brian V Balgobind; Kees Koedooder; Diego Ordoñez Zúñiga; Raquel Dávila Fajardo; Coen R N Rasch; Bradley R Pieters
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

2.  Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.

Authors:  Ingo U Teudt; György Kovàcs; Matthias Ritter; Corinna Melchert; Tamer Soror; Barbara Wollenberg; Jens E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

Review 3.  The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Małgorzata Wierzbicka; Anna Bartochowska; Vratislav Strnad; Primož Strojan; William M Mendenhall; Louis B Harrison; Alessandra Rinaldo; Puja Sahai; Susanne Wiegand; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-22       Impact factor: 2.503

4.  Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results.

Authors:  Vratislav Strnad; Michael Lotter; Stephan Kreppner; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2015-01-10       Impact factor: 3.621

Review 5.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

Review 6.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

Review 7.  Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?

Authors:  Luboš Tuček; Milan Vošmik; Jiří Petera
Journal:  Cancers (Basel)       Date:  2022-01-03       Impact factor: 6.639

8.  Salvage brachytherapy with or without external beam radiotherapy for oral or oropharyngeal squamous cell carcinomas in previously irradiated areas: carcinologic and toxicity outcomes of 25 patients.

Authors:  Pierre-Marie Pialat; Michael Mounie; Fabien Podeur; Frédéric Gassa; Jean-Philippe Suchaud; Bertrand Fleury; Severine Racadot; Anne-Agathe Serre; Pascal Pommier
Journal:  J Contemp Brachytherapy       Date:  2021-08-24

9.  Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes.

Authors:  Anthony Pham; Shruthi Arora; A Gabriella Wernicke; David I Kutler; Marc Cohen; William Kuhel; Samuel Trichter; Dattatreyudu Nori; Silvia C Formenti; Bhupesh Parashar
Journal:  J Contemp Brachytherapy       Date:  2015-12-30

10.  Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.

Authors:  M Ritter; I U Teudt; J E Meyer; U Schröder; G Kovács; B Wollenberg
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.